Who are Pentoxifylline plus Metadoxine's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/pentoxifylline-plus-metadoxine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Pentoxifylline plus Metadoxine — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Pentoxifylline plus Metadoxine (Pentoxifylline plus Metadoxine) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Rheological agent plus metabolic support agent. Area: Hepatology; Vascular/Microcirculation.

marketed Rheological agent plus metabolic support agent Hepatology; Vascular/Microcirculation Small molecule Live · refreshed every 30 min

Target snapshot

Pentoxifylline plus Metadoxine (Pentoxifylline plus Metadoxine) — Hospital General de Mexico. Pentoxifylline improves blood flow and reduces blood viscosity while metadoxine enhances cellular metabolism and liver function, together addressing microcirculatory dysfunction and metabolic support.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Pentoxifylline plus Metadoxine TARGET	Pentoxifylline plus Metadoxine	Hospital General de Mexico	marketed	Rheological agent plus metabolic support agent

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Rheological agent plus metabolic support agent class)

Hospital General de Mexico · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Pentoxifylline plus Metadoxine — Competitive Intelligence Brief. https://druglandscape.com/ci/pentoxifylline-plus-metadoxine. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab